Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by Aarcoron Jun 25, 2022 1:17pm
174 Views
Post# 34782394

RE:RE:Bioasis Connections

RE:RE:Bioasis ConnectionsPublic companies that have an interest in future funding do not want to have anything positive left to the public to decipher.

All the speculation over the last decade about what/who may be linked or not linked and what may or may not be happening in the background is garbage.  Competent management finds ways to make positive developments straightforward to interpret.  This in turn, leads to higher market cap and the ability to raise funds.

People on this board like to say that pre-clinical and clinical biotech is a crapshoot and it is all speculation.  Almost always that is presented in the binary form of a drug and a trial and a yes/no answer.  That is where the speculation is supposed to lie.  Not so much in the ability of a management team to actually perform their jobs competently. Every single management team and BoD over the last 10 years has been incompetent and unable to advance xb3 forward.  That is the sole reason this stock is worth $10M CAD.  The management team is simply not investable and no amount of connect the dots BS will change that.

Still holding my breath that this new search for a strategic change in direction will lead to the complete removal of Rathjen and her worthless BoD.


<< Previous
Bullboard Posts
Next >>